Skip to main content
Top
Published in: BMC Health Services Research 1/2017

Open Access 01-12-2017 | Research article

Impact on healthcare resource utilization of multiple sclerosis in Spain

Authors: Antoni Sicras-Mainar, Elena Ruíz-Beato, Ruth Navarro-Artieda, Jorge Maurino

Published in: BMC Health Services Research | Issue 1/2017

Login to get access

Abstract

Background

Multiple sclerosis (MS) is a chronic disease with a high socioeconomic impact. The aim of this study was to assess healthcare resources utilization and costs in a sample of patients with MS.

Methods

A retrospective, cohort study was conducted using electronic medical records from 19 primary care centres in Asturias and Catalonia, Spain. Adult patients diagnosed with MS were distributed into two groups according to the Expanded Disability Status Scale (EDSS) score: 0–3.5 (no-moderate disability) and 4–9.5 (severe disability). Healthcare (direct cost) and non-healthcare costs (work productivity losses) were analysed. An analysis of covariance (ANCOVA) was used for correction, p < 0.05. A multiple regression model was performed to obtain the variables associated with costs.

Results

A total of 222 patients were analyzed; mean (SD) age: 45.5 (12.5) years, 64.4% female, and 62.2% presented a diagnosis of relapsing-remitting MS. Median EDSS score was 2.5, with 68.5% of the patients with no to moderate disability. The mean annual cost per MS patient was €25,103. For no-moderate and severe disability, the ANCOVA-adjusted mean annual cost was €23,157 and €29,242, respectively (p = 0.013). Direct costs and MS disease-modifying therapy accounted for 39.4% and 31.7% of the total costs, respectively. The total costs were associated with number of relapses (β = 0.135, p = 0.001), time since diagnosis (β = 0.281, p = 0.023), and age (β = 0.198, p = 0.037).

Conclusions

Multiple sclerosis imposes a substantial economic burden on the Spanish National Health System, patients and society as a whole. Costs significantly correlated with disease progression.
Literature
1.
go back to reference Vidal-Jordana A, Montalban X. Multiple sclerosis: epidemiologic, clinical, and therapeutic aspects. Neuroimaging Clin N Am. 2017;27:195–204.CrossRefPubMed Vidal-Jordana A, Montalban X. Multiple sclerosis: epidemiologic, clinical, and therapeutic aspects. Neuroimaging Clin N Am. 2017;27:195–204.CrossRefPubMed
2.
go back to reference Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin. 2016;34:919–39.CrossRefPubMed Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin. 2016;34:919–39.CrossRefPubMed
3.
go back to reference Otero-Romero S, Roura P, Solà J, Altimiras J, Sastre-Garriga J, Nos C, Vaqué J, Montalban X. Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain. Mult Scler. 2013;19:245–8.CrossRefPubMed Otero-Romero S, Roura P, Solà J, Altimiras J, Sastre-Garriga J, Nos C, Vaqué J, Montalban X. Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain. Mult Scler. 2013;19:245–8.CrossRefPubMed
4.
go back to reference Candeliere-Merlicco A, Valero-Delgado F, Martínez-Vidal S, Lastres-Arias MDC, Aparicio-Castro E, Toledo-Romero F, Villaverde-González R. Prevalence of multiple sclerosis in Health District III, Murcia, Spain. Mult Scler Relat Disord. 2016;9:31–5.CrossRefPubMed Candeliere-Merlicco A, Valero-Delgado F, Martínez-Vidal S, Lastres-Arias MDC, Aparicio-Castro E, Toledo-Romero F, Villaverde-González R. Prevalence of multiple sclerosis in Health District III, Murcia, Spain. Mult Scler Relat Disord. 2016;9:31–5.CrossRefPubMed
5.
go back to reference Fernández O, Fernández V, Guerrero M, León A, López-Madrona JC, Alonso A, Bustamante R, Tamayo JA, Romero F, Bravo M, Luque G, García L, Sanchís G, San Roman C, Romero M, Papais-Alvarenga M, de Ramon E. Multiple sclerosis prevalence in Malaga, southern Spain estimated by the capture-recapture method. Mult Scler. 2012;18:372–6.CrossRefPubMed Fernández O, Fernández V, Guerrero M, León A, López-Madrona JC, Alonso A, Bustamante R, Tamayo JA, Romero F, Bravo M, Luque G, García L, Sanchís G, San Roman C, Romero M, Papais-Alvarenga M, de Ramon E. Multiple sclerosis prevalence in Malaga, southern Spain estimated by the capture-recapture method. Mult Scler. 2012;18:372–6.CrossRefPubMed
6.
go back to reference Torkildsen Ø, Myhr K-M, Bø L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol. 2016;23(Suppl 1):18–27.CrossRefPubMed Torkildsen Ø, Myhr K-M, Bø L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol. 2016;23(Suppl 1):18–27.CrossRefPubMed
7.
go back to reference Ayuso GI. Multiple sclerosis: socioeconomic effects and impact on quality of life. Med Clínica. 2014;143(Suppl 3):7–12.CrossRef Ayuso GI. Multiple sclerosis: socioeconomic effects and impact on quality of life. Med Clínica. 2014;143(Suppl 3):7–12.CrossRef
8.
go back to reference Rivera-Navarro J, Benito-León J, Oreja-Guevara C, Pardo J, Dib WB, Orts E, et al. Burden and health-related quality of life of Spanish caregivers of persons with multiple sclerosis. Mult Scler. 2009;15:1347–55.CrossRefPubMed Rivera-Navarro J, Benito-León J, Oreja-Guevara C, Pardo J, Dib WB, Orts E, et al. Burden and health-related quality of life of Spanish caregivers of persons with multiple sclerosis. Mult Scler. 2009;15:1347–55.CrossRefPubMed
9.
go back to reference Bøe Lunde HM, Telstad W, Grytten N, Kyte L, Aarseth J, Myhr K-M, et al. Employment among patients with multiple sclerosis-a population study. PLoS One. 2014;9:e103317.CrossRefPubMedPubMedCentral Bøe Lunde HM, Telstad W, Grytten N, Kyte L, Aarseth J, Myhr K-M, et al. Employment among patients with multiple sclerosis-a population study. PLoS One. 2014;9:e103317.CrossRefPubMedPubMedCentral
10.
go back to reference Ernstsson O, Gyllensten H, Alexanderson K, Tinghög P, Friberg E, Norlund A. Cost of illness of multiple sclerosis - a systematic review. PLoS One. 2016;11:e0159129.CrossRefPubMedPubMedCentral Ernstsson O, Gyllensten H, Alexanderson K, Tinghög P, Friberg E, Norlund A. Cost of illness of multiple sclerosis - a systematic review. PLoS One. 2016;11:e0159129.CrossRefPubMedPubMedCentral
11.
go back to reference Olesen J, Gustavsson A, Svensson M, Wittchen H-U, Jönsson B. CDBE2010 study group, et al. the economic cost of brain disorders in Europe. Eur J Neurol. 2012;19:155–62.CrossRefPubMed Olesen J, Gustavsson A, Svensson M, Wittchen H-U, Jönsson B. CDBE2010 study group, et al. the economic cost of brain disorders in Europe. Eur J Neurol. 2012;19:155–62.CrossRefPubMed
12.
go back to reference Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23:1123–36.CrossRefPubMedPubMedCentral Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23:1123–36.CrossRefPubMedPubMedCentral
13.
go back to reference Salter A, Thomas NP, Tyry T, Cutter GR, Marrie RA. A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS registry. Mult Scler. 2017; [Epub ahead of print] Salter A, Thomas NP, Tyry T, Cutter GR, Marrie RA. A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS registry. Mult Scler. 2017; [Epub ahead of print]
14.
go back to reference Parés-Badell O, Barbaglia G, Jerinic P, Gustavsson A, Salvador-Carulla L, Alonso J. Cost of disorders of the brain in Spain. PLoS One. 2014;9:e105471.CrossRefPubMedPubMedCentral Parés-Badell O, Barbaglia G, Jerinic P, Gustavsson A, Salvador-Carulla L, Alonso J. Cost of disorders of the brain in Spain. PLoS One. 2014;9:e105471.CrossRefPubMedPubMedCentral
15.
go back to reference Fernández O, Calleja-Hernández MA, Meca-Lallana J, Oreja-Guevara C, Polanco A, Pérez-Alcántara F. Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Rev Pharmacoecon Outcomes Res. 2017;17:321–33.CrossRefPubMed Fernández O, Calleja-Hernández MA, Meca-Lallana J, Oreja-Guevara C, Polanco A, Pérez-Alcántara F. Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Rev Pharmacoecon Outcomes Res. 2017;17:321–33.CrossRefPubMed
16.
go back to reference Lamberts H, Wood M, Hofmans-Okkes I. The international classification of primary Care in the European Community. With a multi-language layer. 2nd ed. Oxford: Oxford University Press; 1993. Lamberts H, Wood M, Hofmans-Okkes I. The international classification of primary Care in the European Community. With a multi-language layer. 2nd ed. Oxford: Oxford University Press; 1993.
18.
go back to reference Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.CrossRefPubMed Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.CrossRefPubMed
19.
go back to reference World Health Organization. The anatomical therapeutic chemical ATC classification system. Geneva: World Health Organization; 1991. World Health Organization. The anatomical therapeutic chemical ATC classification system. Geneva: World Health Organization; 1991.
20.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed
21.
go back to reference Weiner JP, Starfield BH, Steinwachs DM, Mumford LM. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care. 1991;29:452–72.CrossRefPubMed Weiner JP, Starfield BH, Steinwachs DM, Mumford LM. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care. 1991;29:452–72.CrossRefPubMed
24.
go back to reference Moccia M, Palladino R, Lazillo R, Triassi M, Brescia Morra V. Predictors of the 10-year direct costs for treating multiple sclerosis. Acta Neurol Scand. 2017;135:522–8.CrossRefPubMed Moccia M, Palladino R, Lazillo R, Triassi M, Brescia Morra V. Predictors of the 10-year direct costs for treating multiple sclerosis. Acta Neurol Scand. 2017;135:522–8.CrossRefPubMed
25.
26.
go back to reference Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16:639–47.CrossRefPubMed Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16:639–47.CrossRefPubMed
27.
go back to reference Gyllesten H, Wiberg M, Alexanderson K, Norlund A, Friberg E, Hillert J, et al. Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age. Eur J Health Econ. 2017; https://doi.org/10.1007/s10198-017-0894-6. [Epub ahead of print]. Gyllesten H, Wiberg M, Alexanderson K, Norlund A, Friberg E, Hillert J, et al. Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age. Eur J Health Econ. 2017; https://​doi.​org/​10.​1007/​s10198-017-0894-6. [Epub ahead of print].
28.
go back to reference Moccia M, Palladino R, Lazillo R, Carotenuto A, Russo CV, Triassi M, et al. Healthcare costs for treating relapsing multiple sclerosis and the risk of progression: a retrospective Italian cohort study from 2001 to 2015. PLoS One. 2017;12:e0169489.CrossRefPubMedPubMedCentral Moccia M, Palladino R, Lazillo R, Carotenuto A, Russo CV, Triassi M, et al. Healthcare costs for treating relapsing multiple sclerosis and the risk of progression: a retrospective Italian cohort study from 2001 to 2015. PLoS One. 2017;12:e0169489.CrossRefPubMedPubMedCentral
29.
go back to reference Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012;18(2 Suppl):7–15.CrossRefPubMed Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012;18(2 Suppl):7–15.CrossRefPubMed
30.
go back to reference Marziniak M, Ghorab K, Kozubski W, et al. Variations in multiple sclerosis practice within Europe - is it time for a new treatment guideline? Mult Scler Relat Disord. 2016;8:35–44.CrossRefPubMed Marziniak M, Ghorab K, Kozubski W, et al. Variations in multiple sclerosis practice within Europe - is it time for a new treatment guideline? Mult Scler Relat Disord. 2016;8:35–44.CrossRefPubMed
31.
go back to reference Kobelt G, Berg J, Lindgren P, Izquierdo G, Sánchez-Soliño O, Pérez-Miranda J, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ. 2006;7(Suppl. 2):S65–74.CrossRefPubMed Kobelt G, Berg J, Lindgren P, Izquierdo G, Sánchez-Soliño O, Pérez-Miranda J, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ. 2006;7(Suppl. 2):S65–74.CrossRefPubMed
32.
go back to reference Casado V, Martínez-Yélamos S, Martínez-Yélamos A, Carmona O, Alonso L, Romero L, et al. Direct and indirect costs of multiple sclerosis in Baix Llobregat (Catalonia, Spain), according to disability. BMC Health Serv Res. 2006;6:143.CrossRefPubMedPubMedCentral Casado V, Martínez-Yélamos S, Martínez-Yélamos A, Carmona O, Alonso L, Romero L, et al. Direct and indirect costs of multiple sclerosis in Baix Llobregat (Catalonia, Spain), according to disability. BMC Health Serv Res. 2006;6:143.CrossRefPubMedPubMedCentral
33.
go back to reference Casado V, Romero L, Gubieras L, Alonso L, Moral E, Martinez-Yelamos S, et al. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain. Mult Scler. 2007;13:800–4.CrossRefPubMed Casado V, Romero L, Gubieras L, Alonso L, Moral E, Martinez-Yelamos S, et al. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain. Mult Scler. 2007;13:800–4.CrossRefPubMed
34.
go back to reference Karampampa K, Gustavsson A, Miltenburger C, Mora S, Arbizu T. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain. Mult Scler. 2012;18:35–9.CrossRefPubMed Karampampa K, Gustavsson A, Miltenburger C, Mora S, Arbizu T. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain. Mult Scler. 2012;18:35–9.CrossRefPubMed
35.
go back to reference Motheral B, Brooks J, Clark MA, Crown WH, Davey P, Hutchins D, et al. A checklist for retrospective database studies--report of the ISPOR task force on retrospective databases. Value Health. 2003;6:90–7.CrossRefPubMed Motheral B, Brooks J, Clark MA, Crown WH, Davey P, Hutchins D, et al. A checklist for retrospective database studies--report of the ISPOR task force on retrospective databases. Value Health. 2003;6:90–7.CrossRefPubMed
36.
go back to reference Duquette P, Giacomini PS, Bhan V, Hohol M, Schecter R. Balancing early aggression against risk of progression in multiple sclerosis. Can J Neurol Sci. 2016;43:33–43.CrossRefPubMed Duquette P, Giacomini PS, Bhan V, Hohol M, Schecter R. Balancing early aggression against risk of progression in multiple sclerosis. Can J Neurol Sci. 2016;43:33–43.CrossRefPubMed
37.
go back to reference Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev. 2017;16:658–65.CrossRefPubMed Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev. 2017;16:658–65.CrossRefPubMed
Metadata
Title
Impact on healthcare resource utilization of multiple sclerosis in Spain
Authors
Antoni Sicras-Mainar
Elena Ruíz-Beato
Ruth Navarro-Artieda
Jorge Maurino
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2017
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-017-2807-x

Other articles of this Issue 1/2017

BMC Health Services Research 1/2017 Go to the issue